Amphera B.V.

Amphera was founded in December 2012. Amphera develops an immunotherapy for mesothelioma, cancer induced by asbestos. By triggering the patient’s own immune defense system, growth of cancer cells may be stopped or inhibited.

The European Commission granted orphan designation (EU/3/13/1229, 16 January 2014) to Amphera for her innovative immunotherapy for the treatment of malignant mesothelioma.

For more information: www.amphera.nl